Orna
Founded 2019 · 114 employees on LinkedIn · 3 known investors
Find your way into Orna
122 people in our graph share verified history with the Orna team — schools, employers, funds. One of them is your warm intro.
Noubar Afeyanunlockedknows Siva Sakhamuri · together at Omega Therapeutics (overlapped)
knows the team · via Alnylam
×10knows the team · via MPM BioImpact
Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
Founders & leadership
JB
Joe BolenChief Executive Officer
JB
Joe Bolen, Ph.D.Chief Executive Officer
HD
Hope D'Oyley-Gay, JDChief Legal Officer
CL
Ciaran Lawlor, Ph.D.Chief Operating Officer
FN
Frank Neumann, M.D., Ph.D.Chief Medical Officer
SS
Siva SakhamuriinChief Technology OfficerChief Technology Officer of Orna Therapeutics, Siva Sakhamuri brings biotechnology industry experience with expertise in manufacturing operations, process development, quality assurance, and GMP compliance across drug development lifecycles.
BS
Investors · 3
Funding
SEC filings, press & company announcements- Undisclosed amountSeed RoundJun 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 5
by search overlap
ロゴマーク：AIRNA52 shared keywordsAIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA. The company targets diseases where the underlying genetic mechanism is well-established and difficult to address with existing therapeutic approaches.
Ronatherapeutics48 shared keywordsRona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.
Averna Therapeutics46 shared keywordsAverna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
Transcode Therapeutics44 shared keywordsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
Innorna43 shared keywordsInnorna develops mRNA-based therapeutics built on a proprietary platform featuring a lipid library of over 100,000 ionizable lipid structures and targeted LNP delivery systems. The company's pipeline spans vaccines, protein replacement therapies for chronic metabolic diseases, and in vivo immunotherapies for autoimmune conditions, with four candidates in clinical trials.
Companies competing with Orna for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Orna do?
- Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
- Who are Orna's investors?
- Orna's investors include Astellas Venture Management LLC, MPM BioImpact, Taiho Ventures, LLC.